MedTrace Logo

Macitentan in Pulmonary Hypertension of Sickle Cell Disease

NCT02651272 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-12-08

Study results available
· View outcomes & findings →

Summary

This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.

Conditions

Interventions

DRUG

macitentan

10mg macitentan tablets

Sponsors & Collaborators

  • Actelion

    collaborator INDUSTRY

  • Boston University

    lead OTHER

Principal Investigators

  • Elizabeth Klings, MD · Boston University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-12-18
Completion
2019-12-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02651272 on ClinicalTrials.gov